Utilizing smaller mAb fragments (e.g., scFv, F(ab′)2, scFv-Fc) that target CSPG4 [46,49] could be employed to improve tumor penetration and normal tissue clearance kinetics, and thus enhance therapeutic efficacy and tolerability. Here, CSPG4 is linked to neoplasm.